Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients
Phase 2
Completed
- Conditions
- Diabetic Foot InfectionDiabetic Foot
- Interventions
- Other: Standard of Care
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Microbion Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT05174806
- Locations
- 🇺🇸
Parkland Comprehensive Wound Center, Dallas, Texas, United States
🇺🇸Limb Preservation Platform, Inc., Fresno, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Microbion Corporation
- Target Recruit Count
- 52
- Registration Number
- NCT02723539
- Locations
- 🇺🇸
Futuro Clinical Trials, LLC, McAllen, Texas, United States
🇺🇸Limb Preservation Platform, Inc, Fresno, California, United States
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Microbion Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02436876
- Locations
- 🇺🇸
LifeBridge Health, Inc., Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸OhioHealth Research Institute, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath